Enhancing Effects of Lactobacillus brevis CQPC12 on Antibiotic-Induced Motor Dysfunction in Mice | Chapter 4 | Application of Probiotics in Exercise and Thrombosis Inhibition

 

Lactobacillus brevis is a heterofermentative gram-positive organism that can be isolated from milk, cheese, sauerkraut, sourdough, silage, and the mouth and intestinal tract of humans. Lactobacillus brevis CQPC12, a lactic acid bacterial strain with strong in vitro resistance and potential for gut colonisation. This study evaluated the neuroprotective and performance-enhancing effects of Lactobacillus brevis CQPC12 (LBCQPC12), focusing on its anti-inflammatory and antioxidant properties in a murine model of systemic perturbation. A state of systemic dysbiosis and inflammation was induced in mice via intraperitoneal injection of a broad-spectrum antibiotic cocktail (containing neomycin, vancomycin, amphotericin B, ampicillin, and metronidazole) combined with lipopolysaccharide. Following intervention with LBCQPC12, comprehensive assessments were conducted. Functional performance was evaluated through endurance running and weight-loaded swimming tests. Histopathological analysis of brain tissue was performed using hematoxylin-eosin (H&E) staining. Systemic and cerebral oxidative stress and inflammatory markers were quantified, and gene expression profiles related to neurotrophic signalling, inflammation, and vascular metabolism in the brain and skeletal muscle were analysed via quantitative polymerase chain reaction (qPCR). The results demonstrated that LBCQPC12 treatment significantly improved physical endurance, as indicated by prolonged running and swimming durations. It also effectively mitigated systemic and cerebral oxidative stress by elevating levels of total superoxide dismutase (T-SOD) and glutathione (GSH), while reducing malondialdehyde (MDA). Concurrently, LBCQPC12 exerted anti-inflammatory effects, lowering serum and brain concentrations of pro-inflammatory cytokines interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α), while elevating the anti-inflammatory cytokine IL-10, and reducing the liver index. At the molecular level, LBCQPC12 upregulated key genes in the brain-derived neurotrophic factor (BDNF) signalling pathway, including protein kinase B 1 (AKT1), cAMP-response element binding protein (CREB), BDNF itself, and extracellular regulated protein kinases 1 (ERK1). In skeletal muscle, it enhanced the expression of metabolic and angiogenic factors such as vascular endothelial growth factor A (VEGF-A), glucose transporter 1 (GLUT-1), GLUT-4, and hypoxia-inducible factor-1 alpha (HIF-1α). In conclusion, Lactobacillus brevis CQPC12 demonstrates substantial potential in counteracting antibiotic-induced central nervous system oxidative inflammation and skeletal muscle impairment, thereby preserving motor function. These findings position LBCQPC12 as a promising candidate for the development of next-generation functional probiotic formulations aimed at supporting neuromotor health.

 

 

Author(s) Details

 

Jiyou Wu
Sports Department, Yunnan Normal University, Kunming 650500, Yunnan, China.

 

Xiaoguang Yang
College of Physical Education, Yan’an University, Yan’an 716000, Shaanxi, China.

 

Yuhua Yang

Department of Sport Management, College of Humanities and Law, Beijing University of Chemical Technology, Beijing 100029, China.

 

Please see the book here :- https://doi.org/10.9734/bpi/mono/978-81-998509-9-6/CH4